Veracyte, Inc. (NASDAQ:VCYT) CFO Rebecca Chambers Sells 527 Shares

Veracyte, Inc. (NASDAQ:VCYT) CFO Rebecca Chambers sold 527 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $43.85, for a total transaction of $23,108.95. Following the transaction, the chief financial officer now directly owns 113,510 shares in the company, valued at approximately $4,977,413.50. This represents a 0.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Rebecca Chambers also recently made the following trade(s):

• On Tuesday, December 3rd, Rebecca Chambers sold 7,000 shares of Veracyte stock. The stock was sold at an average price of $43.23, for a total transaction of $302,610.00.

Veracyte Stock Up 3.3 %

Shares of Veracyte stock traded up $1.45 during midday trading on Wednesday, hitting $45.20. The company’s stock had a trading volume of 928,902 shares, compared to its average volume of 809,425. The firm has a market capitalization of $3.50 billion, a P/E ratio of -301.33 and a beta of 1.71. The stock has a 50-day simple moving average of $42.49 and a 200-day simple moving average of $35.88. Veracyte, Inc. has a 1-year low of $18.61 and a 1-year high of $47.32.

Veracyte (NASDAQ:VCYT) last issued its earnings results on Wednesday, November 6th. The biotechnology company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.03 by $0.16. The business had revenue of $115.86 million during the quarter, compared to analysts’ expectations of $109.81 million. Veracyte had a positive return on equity of 3.02% and a negative net margin of 2.18%. Veracyte’s revenue was up 28.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.03) earnings per share. As a group, sell-side analysts predict that Veracyte, Inc. will post 0.38 earnings per share for the current year.

Institutional Trading of Veracyte

A number of institutional investors have recently bought and sold shares of VCYT. US Bancorp DE lifted its position in shares of Veracyte by 57.4% in the fourth quarter. US Bancorp DE now owns 1,774 shares of the biotechnology company’s stock worth $70,000 after buying an additional 647 shares during the last quarter. Principal Securities Inc. lifted its position in shares of Veracyte by 34.1% in the fourth quarter. Principal Securities Inc. now owns 1,909 shares of the biotechnology company’s stock worth $76,000 after buying an additional 485 shares during the last quarter. Castleview Partners LLC acquired a new stake in shares of Veracyte in the third quarter worth about $87,000. Values First Advisors Inc. acquired a new stake in shares of Veracyte in the third quarter worth about $91,000. Finally, KBC Group NV lifted its position in shares of Veracyte by 13.7% in the third quarter. KBC Group NV now owns 2,677 shares of the biotechnology company’s stock worth $91,000 after buying an additional 323 shares during the last quarter.

Analyst Ratings Changes

A number of brokerages have recently commented on VCYT. UBS Group raised their target price on shares of Veracyte from $43.00 to $46.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Needham & Company LLC raised their target price on shares of Veracyte from $44.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Scotiabank raised their target price on shares of Veracyte from $40.00 to $44.00 and gave the company a “sector outperform” rating in a research note on Friday, November 8th. Guggenheim began coverage on Veracyte in a research note on Thursday, October 10th. They set a “buy” rating and a $40.00 price objective for the company. Finally, Wolfe Research started coverage on Veracyte in a research note on Friday, November 15th. They set an “outperform” rating and a $50.00 price objective for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Veracyte presently has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Veracyte Company Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.